UNSPSC 51161730: Fenspiride hydrochloride

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 832NBX878V, chemically known as 8-phenethyl-1-oxa-3,8-diazaspiro(4.5)decan-2-one monohydrochloride but more generally known as fenspiride hydrochloride, which bears US NIH Compound Identifier 68626. European Medicines Agency schedules Fenspiride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02128MIG.

UNSPSC 51161730 Fenspiride hydrochloride is a Commodity code that in current state and local procurement practice covers pharmaceutical products and related pharmacy services far broader than the code's nominal chemical name suggests. Recent solicitations show state and local governments buying naloxone and drug deactivation systems for community health initiatives, on-site pharmacy services for employee health plans, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and direct-to-manufacturer prescription programs. Issuing bodies include county health departments and community health offices, county government human resources and benefits departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across state and local members. The mix reflects both direct county procurement and participation in cooperative vehicles that standardize pharmaceutical sourcing across multiple jurisdictions.

Recent activity spans Florida, Georgia, Texas, and Minnesota. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to its community health building. Hall County, Georgia issued RFQ/P #47-010 in May 2026 (due June 4, 2026) for on-site pharmacy services at its family health center clinic to serve approximately 3,005 employees and retirees across multiple health plan populations, with an 80/20 technical-to-cost evaluation weighting and a contract term beginning January 1, 2027. The Texas Health and Human Services Commission posted RFI No. HHS0017013 in April 2026 to gather vendor capability and market intelligence on direct-to-manufacturer prescription programs before issuing formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities, with awarded contracts effective July 1, 2026 and pricing weighted at 75 percent of the evaluation score.